Nature Reviews Clinical Oncology最新文献

筛选
英文 中文
T cell redirection in high-risk smouldering multiple myeloma: can deep responses prevent progression to multiple myeloma? T细胞重定向在高危阴燃性多发性骨髓瘤中的作用:深度应答能否阻止多发性骨髓瘤的进展?
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-11-10 DOI: 10.1038/s41571-026-01230-2
María-Victoria Mateos
{"title":"T cell redirection in high-risk smouldering multiple myeloma: can deep responses prevent progression to multiple myeloma?","authors":"María-Victoria Mateos","doi":"10.1038/s41571-026-01230-2","DOIUrl":"https://doi.org/10.1038/s41571-026-01230-2","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":94.6,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149387298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC. Divarasib在NSCLC中的疗效优于第一代KRAS-G12C抑制剂。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-11-09 DOI: 10.1038/s41571-026-01233-z
Diana Romero
{"title":"Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC.","authors":"Diana Romero","doi":"10.1038/s41571-026-01233-z","DOIUrl":"https://doi.org/10.1038/s41571-026-01233-z","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":94.6,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risvutatug rezetecan has promising efficacy in osteosarcoma. 瑞沙替康治疗骨肉瘤有良好的疗效。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-11-09 DOI: 10.1038/s41571-026-01228-w
David Killock
{"title":"Risvutatug rezetecan has promising efficacy in osteosarcoma.","authors":"David Killock","doi":"10.1038/s41571-026-01228-w","DOIUrl":"https://doi.org/10.1038/s41571-026-01228-w","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":94.6,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging strategies for paediatric cancer predisposition: detection, surveillance and prevention. 儿童癌症易感性的新战略:检测、监测和预防。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-11-06 DOI: 10.1038/s41571-026-01217-z
Garrett M Brodeur, Suzanne P MacFarland, Gabriel C Brodeur, Christopher C Porter, Anita Villani, David Malkin
{"title":"Emerging strategies for paediatric cancer predisposition: detection, surveillance and prevention.","authors":"Garrett M Brodeur, Suzanne P MacFarland, Gabriel C Brodeur, Christopher C Porter, Anita Villani, David Malkin","doi":"10.1038/s41571-026-01217-z","DOIUrl":"https://doi.org/10.1038/s41571-026-01217-z","url":null,"abstract":"<p><p>A substantial proportion of childhood cancers occur in children who are genetically predisposed to develop that cancer. Close surveillance of children with cancer predisposition syndromes enables early cancer detection and results in better survival outcomes and less therapy-related toxicity, although many more predisposition syndromes are likely to exist and remain undetected. Building on conventional clinical surveillance protocols, new approaches are being explored, including liquid biopsy, molecular or metabolic biomarkers, enhanced imaging and microbiome profiling for the purposes of both improved surveillance and the discovery of additional predisposing factors. Knowing the specific genes, expressed proteins and biological pathways associated with a specific cancer predisposition syndrome might permit the use of targeted agents or vaccines, as well as the introduction of lifestyle changes to delay, reduce or even eliminate the development of cancer. Preclinical studies investigating the risks and benefits of preventive interventions would be greatly aided by the identification or development of animal models that faithfully recapitulate human syndromes. The incorporation of artificial intelligence to complement the clinical and experimental assessment of cancer risk based on the syndrome, genotype, modifier genes, family history, environmental exposures and other factors will undoubtedly improve the management and, ultimately, the outcomes of children with an increased genetic risk of cancer. In this Perspective, we discuss strategies to identify new cancer predisposition genes, developing approaches to cancer surveillance, emerging efforts for cancer prevention in high-risk patients, and the role of artificial intelligence in improving data analysis and optimizing medical decision-making.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":94.6,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149371300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sacituzumab tirumotecan-pembrolizumab has efficacy in PD-L1-negative NSCLC. Sacituzumab替鲁莫替康-派姆单抗对pd - l1阴性NSCLC有效。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-11-06 DOI: 10.1038/s41571-026-01232-0
Diana Romero
{"title":"Sacituzumab tirumotecan-pembrolizumab has efficacy in PD-L1-negative NSCLC.","authors":"Diana Romero","doi":"10.1038/s41571-026-01232-0","DOIUrl":"https://doi.org/10.1038/s41571-026-01232-0","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":94.6,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149371301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unprecedented OS with the addition of tarlatamab to first-line maintenance therapy for ES-SCLC. 在ES-SCLC的一线维持治疗中加入塔拉他单抗的前所未有的OS。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-11-06 DOI: 10.1038/s41571-026-01227-x
David Killock
{"title":"Unprecedented OS with the addition of tarlatamab to first-line maintenance therapy for ES-SCLC.","authors":"David Killock","doi":"10.1038/s41571-026-01227-x","DOIUrl":"https://doi.org/10.1038/s41571-026-01227-x","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":94.6,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149371302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: Combining locoregional treatments and immunotherapies in patients with unresectable hepatocellular carcinoma. 作者更正:局部治疗和免疫治疗联合治疗不可切除的肝细胞癌。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-11-06 DOI: 10.1038/s41571-026-01229-9
Dania Cioni, Ezequiel Mauro, Dan Feng, Guillem Cano-Segarra, Edward Kim, Jeroen Dekervel, Maxime Ronot, Salvatore Claudio Fanni, Riccardo Lencioni, Josep M Llovet
{"title":"Author Correction: Combining locoregional treatments and immunotherapies in patients with unresectable hepatocellular carcinoma.","authors":"Dania Cioni, Ezequiel Mauro, Dan Feng, Guillem Cano-Segarra, Edward Kim, Jeroen Dekervel, Maxime Ronot, Salvatore Claudio Fanni, Riccardo Lencioni, Josep M Llovet","doi":"10.1038/s41571-026-01229-9","DOIUrl":"https://doi.org/10.1038/s41571-026-01229-9","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":94.6,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149371299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to: 'Interpreting surgical consolidation in oligometastatic gastro-oesophageal cancer'. 回复:“解释少转移性胃食管癌的手术巩固”。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-11-03 DOI: 10.1038/s41571-026-01218-y
Hongcheng Zhu, Florian Lordick, Yelena Y Janjigian, Sun Young Rha, Magnus Nilsson, Kohei Shitara, Richard Owen, Zhen Zhang, Elizabeth C Smyth
{"title":"Reply to: 'Interpreting surgical consolidation in oligometastatic gastro-oesophageal cancer'.","authors":"Hongcheng Zhu, Florian Lordick, Yelena Y Janjigian, Sun Young Rha, Magnus Nilsson, Kohei Shitara, Richard Owen, Zhen Zhang, Elizabeth C Smyth","doi":"10.1038/s41571-026-01218-y","DOIUrl":"https://doi.org/10.1038/s41571-026-01218-y","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":94.6,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149323233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase III data support a novel trifluridine-tipiracil dosing schedule. III期数据支持一种新的trifluridine-tipiracil给药方案。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-11-03 DOI: 10.1038/s41571-026-01226-y
Peter Sidaway
{"title":"Phase III data support a novel trifluridine-tipiracil dosing schedule.","authors":"Peter Sidaway","doi":"10.1038/s41571-026-01226-y","DOIUrl":"https://doi.org/10.1038/s41571-026-01226-y","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":94.6,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149323232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interpreting surgical consolidation in oligometastatic gastro-oesophageal cancer. 少转移性胃食管癌的手术巩固分析。
IF 94.6 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2026-11-03 DOI: 10.1038/s41571-026-01219-x
Sang-Ji Choi
{"title":"Interpreting surgical consolidation in oligometastatic gastro-oesophageal cancer.","authors":"Sang-Ji Choi","doi":"10.1038/s41571-026-01219-x","DOIUrl":"10.1038/s41571-026-01219-x","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":94.6,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149323231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书